

# Review of: "TROPION-Lung01 Results Indicate PFS Benefit with Datopotamab Deruxtecan over Docetaxel in Previously Treated Nonsquamous NSCLC: A Critique and Question"

Asaad Babker<sup>1</sup>

<sup>1</sup> Gulf Medical University, United Arab Emirates

Potential competing interests: No potential competing interests to declare.

-Add a detailed exploration of why PFS benefits may not have impacted OS, such as subsequent therapies, disease biology, or cross-over effects. This would help clinicians better understand the true value of Dato-DXd and contextualize the findings for patient care.

-Provide more detailed information on how pneumonitis cases were managed, their severity, and any long-term consequences. Also, compare the nature and manageability of the grade 3+ toxicities for Dato-DXd vs. docetaxel, helping oncologists better understand the safety profile.

-Recommend longer follow-up periods for future studies to more accurately assess OS and durability of response. Address how this limitation might have impacted the conclusions.